Prime Medicine, Inc.
PRME
$3.67
$0.020.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 55.28% | 647.13% | 739.42% | 550.76% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.28% | 647.13% | 739.42% | 550.76% | -- |
| Cost of Revenue | 4.16% | -5.16% | -9.91% | -31.92% | -44.97% |
| Gross Profit | -2.21% | 11.09% | 14.90% | 34.81% | 46.99% |
| SG&A Expenses | 4.36% | -2.03% | 11.55% | 15.19% | 15.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.67% | -1.71% | -0.68% | 5.08% | 7.40% |
| Operating Income | -2.91% | 4.15% | 2.76% | -3.47% | -5.84% |
| Income Before Tax | -2.69% | 9.99% | 8.40% | 1.12% | 1.28% |
| Income Tax Expenses | -- | -- | -- | -335.09% | 100.00% |
| Earnings from Continuing Operations | -2.69% | 9.99% | 8.35% | 1.22% | 1.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.69% | 9.99% | 8.35% | 1.22% | 1.14% |
| EBIT | -2.91% | 4.15% | 2.76% | -3.47% | -5.84% |
| EBITDA | -2.39% | 4.99% | 3.56% | -2.73% | -5.20% |
| EPS Basic | 17.13% | 29.70% | 27.69% | 25.20% | 23.44% |
| Normalized Basic EPS | 17.49% | 25.40% | 23.54% | 22.08% | 17.78% |
| EPS Diluted | 17.13% | 29.70% | 27.69% | 25.20% | 23.44% |
| Normalized Diluted EPS | 17.49% | 25.40% | 23.54% | 22.08% | 17.78% |
| Average Basic Shares Outstanding | 26.04% | 26.52% | 25.20% | 32.04% | 30.37% |
| Average Diluted Shares Outstanding | 26.04% | 26.52% | 25.20% | 32.04% | 30.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |